The downregulation of Bcl-2 and Bcl-xL genes in cancer cells, combined with the plant’s inhibitory activity against α-glucosidase and α-amylase, provides new insights into its traditional uses and positions it as a promising source for future therapeutic development. The gene discussed is BCL2L1; the disease is cancer.